Compare Abeona Therapeutics Inc (ABEO) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.77. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | XDTE | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.23 | $44.76 |
52-Week Low | $4.17 | $36.00 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
XDTE trades at $39.16, up 0.8% with a bearish technical signal from moving averages. The ETF generates weekly dividend income through covered call strategies on S&P 500 options, though recent analysis highlights NAV erosion concerns despite high yields. Support levels cluster around $38-39 with resistance at $39-40, indicating tight trading range constraints.
The fund's 20%+ dividend yield attracts income investors but faces structural risks from option strategy decay during market shifts. Analyst consensus remains cautious due to NAV performance lagging underlying index gains, requiring careful monitoring of distribution sustainability versus capital preservation trade-offs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
